1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ASTRAZENECA : JP Morgan gives a Buy rating

01/10/2022 | 09:23am EDT

In a research note published by James Gordon, JP Morgan advises its customers to buy the stock. The target price continues to be set at GBX 10000.


ę MarketScreener with dpa-AFX Analyser 2022
All news about ASTRAZENECA PLC
08:48aKepler Cheuvreux Downgrades AstraZeneca to Hold From Buy
MT
07:52aKepler Cheuvreux Drops AstraZeneca To Hold From Buy, Lifts PT
MT
04:59aAstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies aga..
AQ
03:01aFrom storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/17What you need to know about the coronavirus right now
RE
05/17ASTRAZENECA : Deutsche Bank keeps its Buy rating
MD
05/17AstraZeneca Obtains Exclusive Global License To Develop Antibodies Against COVID-19
MT
05/17FTSE 100 lags European peers on strong pound
RE
05/17RQ Biotechnology Ltd Signs Licensing Agreement with AstraZeneca PLC
CI
05/16AstraZeneca Expands License Deal With Drug Discovery Startup to Develop Cancer Therapie..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 739 M - -
Net income 2022 5 294 M - -
Net Debt 2022 22 519 M - -
P/E ratio 2022 37,2x
Yield 2022 2,32%
Capitalization 197 B 197 B -
EV / Sales 2022 5,02x
EV / Sales 2023 4,60x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 127,07 $
Average target price 143,18 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.05%202 631
JOHNSON & JOHNSON2.59%470 547
PFIZER, INC.-14.65%288 063
ABBVIE INC.12.58%273 513
ELI LILLY AND COMPANY6.87%271 308
ROCHE HOLDING AG-14.97%263 868